RedHill Biopharma (RDHL) investor relations material

Company overview and business model

• Specialty biopharmaceutical company focused on U.S. commercialization and development of proprietary drugs for GI diseases, infectious diseases, and oncology.

• Main commercial product is Talicia®, an FDA-approved GI-related drug, marketed in the U.S. in partnership with Cumberland Pharmaceuticals.

• Pipeline includes five therapeutic candidates, with several in mid- to late-stage clinical development, targeting GI and oncology indications.

• Strategy includes in-licensing, acquisitions, and global commercialization through partnerships or independent operations.

Financial performance and metrics

• As of December 31, 2025, total capitalization was $25.3 million actual and $30.7 million pro forma, with a significant accumulated deficit.

• Outstanding debt includes $19.2 million in current liabilities and $1.9 million in non-current liabilities.

• Recent legal proceedings resulted in a final judgment award of over $10.5 million, with ongoing enforcement actions in Korea.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of ADSs by selling shareholders.

• Proceeds from any cash exercise of warrants (up to $13.8 million if fully exercised) are intended for working capital, R&D, and general corporate purposes.